Carlyle group reports 3.8% Jasper stake

Jasper Therapeutics received an Amendment No. 4 to a Schedule 13D from a group of Carlyle- and Abingworth-affiliated entities updating their ownership in its voting common stock.

Rhea-AI Filing Summary

Jasper Therapeutics received an Amendment No. 4 to a Schedule 13D from a group of Carlyle- and Abingworth-affiliated entities updating their ownership in its voting common stock. The group reports beneficial ownership of 1,088,310 shares of common stock, representing 3.8% of the class, based on 27,984,039 shares outstanding as of November 6, 2025. The filing notes that, as of this amendment, the reporting persons have ceased to be beneficial owners of more than five percent of Jasper’s outstanding common stock and that they have not effected any transactions in the stock during the past 60 days. Voting and dispositive power over these shares is shared among the affiliated investment entities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Jasper Therapeutics (JSPR) does the Carlyle-Abingworth group report?

The Carlyle-Abingworth group reports beneficial ownership of 1,088,310 shares of Jasper Therapeutics common stock. This represents 3.8% of the outstanding voting common shares, based on 27,984,039 shares reported outstanding as of November 6, 2025 in Jasper’s Form 10-Q.

What is the significance of the Schedule 13D/A Amendment No. 4 for Jasper Therapeutics (JSPR)?

Amendment No. 4 updates the reporting group’s ownership to 3.8% of Jasper’s common stock. The filing also states the reporting persons have ceased to be beneficial owners of more than five percent of the outstanding shares, an important regulatory disclosure threshold.

Have the Carlyle-Abingworth reporting persons traded Jasper Therapeutics (JSPR) stock recently?

The filing states that during the past 60 days, the reporting persons have not effected any transactions in Jasper Therapeutics common stock. The change in reported percentage reflects their current beneficial ownership relative to shares outstanding.

How many Jasper Therapeutics (JSPR) shares are outstanding for this ownership calculation?

The ownership percentages are calculated using 27,984,039 shares of Jasper Therapeutics common stock outstanding as of November 6, 2025. That share count comes from Jasper’s Quarterly Report on Form 10-Q filed with the SEC on November 10, 2025.

Which entity directly holds Jasper Therapeutics (JSPR) shares for the reporting group?

The filing identifies Abingworth Bioventures VII LP as beneficial owner of 1,088,310 Jasper shares. This includes shares held of record, shares held for its benefit, and stock options, with investment and dispositive power delegated to Abingworth LLP under the group’s structure.

Did the Carlyle-Abingworth group retain shared voting control over Jasper Therapeutics (JSPR) shares?

Yes. The reporting entities show 0 shares with sole voting or dispositive power and 1,088,310 shares with shared voting and shared dispositive power. Multiple affiliated entities may be deemed to share beneficial ownership under this structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 05:29 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Jasper Therapeutics, Inc.

(Name of Issuer)

Voting Common Stock, par value $0.0001 per share

(Title of Class of Securities)

471871202

(CUSIP Number)

Jeffrey Ferguson
The Carlyle Group, 1001 Pennsylvania Avenue, NW, Suite 220S
Washington, DC, 20004
(202) 729-5626

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/18/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

The Carlyle Group Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

Carlyle Holdings I GP Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

Carlyle Holdings I GP Sub L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Limited Liability Company

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

Carlyle Holdings I L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

CG Subsidiary Holdings L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Limited Liability Company

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

TC Group, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Limited Liability Company

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

Carlyle Investment Management L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Limited Liability Company

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

Carlyle Genesis UK LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Limited Liability Company

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

Abingworth LLP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 471871202

1

Name of reporting person

Abingworth Bioventures VII LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,310.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,310.00

11

Aggregate amount beneficially owned by each reporting person

1,088,310.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Voting Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Jasper Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 2200 Bridge Pkwy, Suite #102, Redwood City, CALIFORNIA , 94065.
Item 1 Comment: Explanatory Note This Amendment No. 4 to Schedule 13D ("Amendment No. 4") amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the "SEC") on October 4, 2021 (as amended to date, the "Schedule 13D"), relating to the shares of voting common stock, par value $0.0001 per share (the "Common Stock"), of Jasper Therapeutics, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, based on 27,984,039 shares of Common Stock outstanding as of November 6, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 10, 2025. Abingworth Bioventures VII LP is the beneficial owner of 1,088,310 shares of Common Stock, or approximately 3.8% of the shares of Common Stock outstanding, which include (i) 1,066,189 shares of Common Stock held of record by Abingworth Bioventures VII LP, (ii) 2,117 shares of Common Stock held for the benefit of Abingworth Bioventures VII LP and (iii) 20,004 shares of Common Stock underlying stock options held for the benefit of Abingworth Bioventures VII LP. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VII LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.
(b)	Sole power to vote or to direct the vote: 0 Shared power to vote or to direct the vote: 1,088,310 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or to direct the disposition: 1,088,310
(c)	During the past 60 days, the Reporting Persons have not effected any transactions with respect to the Common Stock.
(d)	None.
(e)	As of the date hereof, the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding shares of Common Stock.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Carlyle Group Inc.

Signature:	/s/ Anne K. Frederick
Name/Title:	Anne K. Frederick, Corporate Secretary
Date:	02/18/2026

Carlyle Holdings I GP Inc.

Signature:	/s/ Anne K. Frederick
Name/Title:	Anne K. Frederick, Managing Director
Date:	02/18/2026

Carlyle Holdings I GP Sub L.L.C.

Signature:	By: Carlyle Holdings I GP Inc., its sole member, /s/ Anne K. Frederick
Name/Title:	Anne K. Frederick, Managing Director
Date:	02/18/2026

Carlyle Holdings I L.P.

Signature:	/s/ Anne K. Frederick
Name/Title:	Anne K. Frederick, Managing Director
Date:	02/18/2026

CG Subsidiary Holdings L.L.C.

Signature:	/s/ Anne K. Frederick
Name/Title:	Anne K. Frederick, Managing Director
Date:	02/18/2026

TC Group, L.L.C.

Signature:	/s/ Anne K. Frederick
Name/Title:	Anne K. Frederick, Managing Director
Date:	02/18/2026

Carlyle Investment Management L.L.C.

Signature:	/s/ Anne K. Frederick
Name/Title:	Anne K. Frederick, Managing Director
Date:	02/18/2026

Carlyle Genesis UK LLC

Signature:	By: Carlyle Investment Management L.L.C., its sole member, /s/ Anne K. Frederick
Name/Title:	Anne K. Frederick, Managing Director
Date:	02/18/2026

Abingworth LLP

Signature:	/s/ Emma O'Reilly
Name/Title:	Emma O'Reilly, Authorized Signatory
Date:	02/18/2026

Abingworth Bioventures VII LP

Signature:	/s/ Emma O'Reilly
Name/Title:	Emma O'Reilly, Authorized Signatory
Date:	02/18/2026